Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates

Experimental and Clinical Transplantation

Volumn 13, Issue , 2015, Pages 201-206

  Rostaing, Lionel ^a,b,c,d   Congy, Nicolas ^b,c,d   Aarnink, Alice ^b,c,d   Maggioni, Sébastien ^a,c   Allal, Asma ^a,c   Sallusto, Federico ^c,e   Game, Xavier ^b,c,d,e   Kamar, Nassim ^a,b,c,d  

^a Department of Nephrology and Organ Transplantation ^*  (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CHU PURPAN   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e Transplantation and Andrology   (France)

Author keywords

Antibody mediated; Apheresis; Eculizumab; HLA sensitized patients; Rejection

Indexed keywords

ALLOANTIBODY; DONOR SPECIFIC ALLOANTIBODY; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PARACETAMOL; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HLA ANTIGEN; IMMUNOADSORBENT; IMMUNOSUPPRESSIVE AGENT;

ABSORBER COLUMN; ACUTE GRAFT REJECTION; ADULT; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DESENSITIZATION; DRUG PULSE THERAPY; FEMALE; FLUORESCENCE ANALYSIS; HEMODIALYSIS; HISTOINCOMPATIBILITY; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MEDICAL DEVICE; MIDDLE AGED; PLASMAPHERESIS; PROSPECTIVE STUDY; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADVERSE EFFECTS; APHERESIS; BLOOD; CASE REPORT; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOADSORBENT; IMMUNOLOGY; PROCEDURES; RISK FACTOR; THERAPEUTIC USE; TIME; TREATMENT OUTCOME;

ADULT; BIOMARKERS; BLOOD COMPONENT REMOVAL; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSORBENTS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939791052     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.mesot2014.O169     Document Type: Article

References (11)

1. Klarenbach SW, Tonelli M, Chui B, Manns BJ. Economic evaluation of dialysis therapies. Nat Rev Nephrol. 2014;10(11):644-652.
2. Garcia GG, Harden P, Chapman J. For The World Kidney Day Steering Committee 2012. The Global role of kidney trans - plantation. J Nephropathol. 2012;1(2):69-76.
3. Segev DL. Innovative strategies in living donor kidney trans - plantation. Nat Rev Nephrol. 2012;8(6):332-338.
4. Becker LE, Süsal C, Morath C. Kidney transplantation across HLA and ABO antibody barriers. Curr Opin Organ Transplant. 2013;18 (4):445-454.
5. Maggioni S, Hermelin M, Faubel E, Allal A, Kamar N, Rostaing L. How to implement immunoadsorption in a polyvalent dialysis unit: a review. J Ren Care. 2014;40(3):164-171.
6. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. N Engl J Med. 2011;365 (4):318-326.
7. Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and costeffectiveness of desensitization using IVIG and rituximab. Transplantation. 2013;95(6):852-858.
8. Al-Jedai A, Alsultan M, Almeshari K, et al. Cost analysis of kidney transplantation in highly sensitized recipients compared to intermittent maintenance hemodialysis. Ann Transplant. 2012;17(4): 82-91.
9. González-Roncero F, Suñer M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal trans - plantation: case reports. Transplant Proc. 2012;44(9):2690-2694.
10. Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc. 2013;45(3):1022- 1025.
11. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;(11):2405-2413.